MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial
- PMID: 12114037
- DOI: 10.1016/S0140-6736(02)09328-5
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial
Abstract
Background: It has been suggested that increased intake of various antioxidant vitamins reduces the incidence rates of vascular disease, cancer, and other adverse outcomes.
Methods: 20,536 UK adults (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching placebo. Intention-to-treat comparisons of outcome were conducted between all vitamin-allocated and all placebo-allocated participants. An average of 83% of participants in each treatment group remained compliant during the scheduled 5-year treatment period. Allocation to this vitamin regimen approximately doubled the plasma concentration of alpha-tocopherol, increased that of vitamin C by one-third, and quadrupled that of beta-carotene. Primary outcomes were major coronary events (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.
Findings: There were no significant differences in all-cause mortality (1446 [14.1%] vitamin-allocated vs 1389 [13.5%] placebo-allocated), or in deaths due to vascular (878 [8.6%] vs 840 [8.2%]) or non-vascular (568 [5.5%] vs 549 [5.3%]) causes. Nor were there any significant differences in the numbers of participants having non-fatal myocardial infarction or coronary death (1063 [10.4%] vs 1047 [10.2%]), non-fatal or fatal stroke (511 [5.0%] vs 518 [5.0%]), or coronary or non-coronary revascularisation (1058 [10.3%] vs 1086 [10.6%]). For the first occurrence of any of these "major vascular events", there were no material differences either overall (2306 [22.5%] vs 2312 [22.5%]; event rate ratio 1.00 [95% CI 0.94-1.06]) or in any of the various subcategories considered. There were no significant effects on cancer incidence or on hospitalisation for any other non-vascular cause.
Interpretation: Among the high-risk individuals that were studied, these antioxidant vitamins appeared to be safe. But, although this regimen increased blood vitamin concentrations substantially, it did not produce any significant reductions in the 5-year mortality from, or incidence of, any type of vascular disease, cancer, or other major outcome.
Comment in
-
Two decades of progress in preventing vascular disease.Lancet. 2002 Jul 6;360(9326):2-3. doi: 10.1016/S0140-6736(02)09358-3. Lancet. 2002. PMID: 12114031 No abstract available.
-
Antioxidant vitamins did not reduce death, vascular events, or cancer in high-risk patients.ACP J Club. 2003 Jan-Feb;138(1):3. ACP J Club. 2003. PMID: 12511115 No abstract available.
Summary for patients in
-
Antioxidants do not prevent heart disease in high-risk individuals.J Fam Pract. 2002 Oct;51(10):810. J Fam Pract. 2002. PMID: 12401142 No abstract available.
Similar articles
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. Lancet. 2002. PMID: 12114036 Clinical Trial.
-
MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.Eur Heart J. 1999 May;20(10):725-41. doi: 10.1053/euhj.1998.1350. Eur Heart J. 1999. PMID: 10329064 Clinical Trial.
-
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7. Lancet. 2003. PMID: 12814710 Clinical Trial.
-
Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases.Curr Cardiol Rep. 2000 Jul;2(4):293-9. doi: 10.1007/s11886-000-0084-4. Curr Cardiol Rep. 2000. PMID: 10953262 Review.
-
Antioxidant vitamins and the prevention of coronary heart disease.Am Fam Physician. 1999 Sep 1;60(3):895-904. Am Fam Physician. 1999. PMID: 10498115 Review.
Cited by
-
An intrinsic mechanism of metabolic tuning promotes cardiac resilience to stress.EMBO Mol Med. 2024 Oct;16(10):2450-2484. doi: 10.1038/s44321-024-00132-z. Epub 2024 Sep 13. EMBO Mol Med. 2024. PMID: 39271959 Free PMC article.
-
Agreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis.JAMA Netw Open. 2024 Sep 3;7(9):e2432296. doi: 10.1001/jamanetworkopen.2024.32296. JAMA Netw Open. 2024. PMID: 39240561 Free PMC article.
-
Scientific opinion on the tolerable upper intake level for preformed vitamin A and β-carotene.EFSA J. 2024 Jun 6;22(6):e8814. doi: 10.2903/j.efsa.2024.8814. eCollection 2024 Jun. EFSA J. 2024. PMID: 38846679 Free PMC article.
-
The Role of Nutrition in the Development and Management of Chronic Obstructive Pulmonary Disease.Nutrients. 2024 Apr 11;16(8):1136. doi: 10.3390/nu16081136. Nutrients. 2024. PMID: 38674827 Free PMC article. Review.
-
Need for a nutrition-specific scientific paradigm for research quality improvement.BMJ Nutr Prev Health. 2023 Jul 14;6(2):383-391. doi: 10.1136/bmjnph-2023-000650. eCollection 2023. BMJ Nutr Prev Health. 2023. PMID: 38618553 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
